Pathway-specific control of striatal neuron vulnerability by corticostriatal cannabinoid CB1 receptors

Cerebral Cortex

Volumn 28, Issue 1, 2018, Pages 307-322

  Ruiz Calvo, Andrea ^a   Maroto, Irene B ^a   Bajo Grañeras, Raquel ^a   Chiarlone, Anna ^a   Gaudioso, Ángel ^a   Ferrero, José J ^a   Resel, Eva ^a   Sánchez Prieto, José ^a   Rodríguez Navarro, José A ^a   Marsicano, Giovanni ^b   Galve Roperh, Ismael ^a   Bellocchio, Luigi ^b   Guzmán, Manuel ^a  

^a UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^b UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

Cannabinoid receptor; Corticostriatal projection; Huntingtin; Medium spiny neuron; Neuroprotection

Indexed keywords

CANNABINOID 1 RECEPTOR; CRE RECOMBINASE; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; HUNTINGTIN; CNR1 PROTEIN, MOUSE; GLUTAMIC ACID; HTT PROTEIN, HUMAN;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CAG REPEAT; CONFOCAL MICROSCOPY; CORPUS STRIATUM; EFFERENT NERVE; GENE DELETION; GENETIC TRANSFECTION; HEK293T CELL LINE; MACROGLIA; MEDIUM SPINY NEURON; MICRODIALYSIS; MOTOR COORDINATION; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; REPORTER GENE; ROTAROD TEST; SIGNAL TRANSDUCTION; SYNAPTOSOME; ANIMAL; ASTROCYTE; BRAIN CORTEX; CELL SURVIVAL; CYTOLOGY; DISEASE MODEL; DRUG EFFECT; GENE VECTOR; GENETICS; HUMAN; HUNTINGTON CHOREA; MALE; METABOLISM; NERVE CELL; NERVE TRACT; PATHOLOGY; PHYSIOLOGY; SYNAPTIC TRANSMISSION; TRANSGENIC MOUSE;

ANIMALS; ASTROCYTES; CELL SURVIVAL; CEREBRAL CORTEX; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; GENETIC VECTORS; GLUTAMIC ACID; HUMANS; HUNTINGTIN PROTEIN; HUNTINGTON DISEASE; MALE; MICE, TRANSGENIC; NEURAL PATHWAYS; NEURONS; RECEPTOR, CANNABINOID, CB1; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; SYNAPTIC TRANSMISSION;

EID: 85044478115     PISSN: 10473211     EISSN: 14602199     Source Type: Journal    
DOI: 10.1093/cercor/bhx285     Document Type: Article

References (72)

1. Alexander GM, Rogan SC, Abbas AI, Armbruster BN, Pei Y, Allen JA, Nonneman RJ, Hartmann J, Moy SS, Nicolelis MA, et al. 2009. Remote control of neuronal activity in transgenic mice expressing evolved G protein-coupled receptors. Neuron. 63:27–39.
2. Andre VM, Fisher YE, Levine MS. 2011. Altered balance of activity in the striatal direct and indirect pathways in mouse models of Huntington’s disease. Front Syst Neurosci. 5:46.
3. Atwood BK, Lovinger DM, Mathur BN. 2014. Presynaptic long-term depression mediated by Gi/o-coupled receptors. Trends Neurosci. 37:663–673.
4. Bagetta V, Picconi B, Marinucci S, Sgobio C, Pendolino V, Ghiglieri V, Fusco FR, Giampa C, Calabresi P. 2011. Dopamine-dependent long-term depression is expressed in striatal spiny neurons of both direct and indirect pathways: implications for Parkinson’s disease. J Neurosci. 31:12513–12522.
5. Bellocchio L, Ruiz-Calvo A, Chiarlone A, Cabanas M, Resel E, Cazalets JR, Blazquez C, Cho YH, Galve-Roperh I, Guzman M.
6. 2016. Sustained Gq-protein signaling disrupts striatal circuits via JNK. J Neurosci. 36:10611–10624.
7. Benraiss A, Wang S, Herrlinger S, Li X, Chandler-Militello D, Mauceri J, Burm HB, Toner M, Osipovitch M, Jim Xu Q, et al. 2016. Human glia can both induce and rescue aspects of disease phenotype in Huntington disease. Nat Commun. 7:11758.
8. 1 cannabinoid receptor signals striatal neuroprotection via a PI3K/Akt/mTORC1/BDNF pathway. Cell Death Differ. 22:1618–1629.
9. Blazquez C, Chiarlone A, Sagredo O, Aguado T, Pazos MR, Resel E, Palazuelos J, Julien B, Salazar M, Borner C, et al. 2011. Loss of striatal type 1 cannabinoid receptors is a key pathogenic factor in Huntington’s disease. Brain. 134:119–136.
10. Castillo PE, Younts TJ, Chavez AE, Hashimotodani Y. 2012. Endocannabinoid signaling and synaptic function. Neuron. 76:70–81.
11. Cepeda C, Levine MS. 1998. Dopamine and N-methyl-D-aspartate receptor interactions in the neostriatum. Dev Neurosci. 20: 1–18.
12. Chen JY, Wang EA, Cepeda C, Levine MS. 2013. Dopamine imbalance in Huntington’s disease: a mechanism for the lack of behavioral flexibility. Front Neurosci. 7:114.
13. 1 cannabinoid receptors with neuroprotective activity. Proc Natl Acad Sci USA. 111: 8257–8262.
14. 1 receptors expressed in GABAergic and glutamatergic neurons in a transgenic mouse model of Huntington’s disease. Neurobiol Dis. 45:983–991.
15. Denovan-Wright EM, Robertson HA. 2000. Cannabinoid receptor messenger RNA levels decrease in a subset of neurons of the lateral striatum, cortex and hippocampus of transgenic Huntington’s disease mice. Neuroscience. 98:705–713.
16. Estrada-Sanchez AM, Burroughs CL, Cavaliere S, Barton SJ, Chen S, Yang XW, Rebec GV. 2015. Cortical efferents lacking mutant huntingtin improve striatal neuronal activity and behavior in a conditional mouse model of Huntington’s disease. J Neurosci. 35:4440–4451.
17. Estrada-Sanchez AM, Rebec GV. 2013. Role of cerebral cortex in the neuropathology of Huntington’s disease. Front Neural Circuits. 7:19.
18. Fernandez-Ruiz J, Moreno-Martet M, Rodriguez-Cueto C, Palomo-Garo C, Gomez-Canas M, Valdeolivas S, Guaza C, Romero J, Guzman M, Mechoulam R, et al. 2011. Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol. 163:1365–1378.
19. Gerdeman GL, Ronesi J, Lovinger DM. 2002. Postsynaptic endocannabinoid release is critical to long-term depression in the striatum. Nat Neurosci. 5:446–451.
20. Ghiglieri V, Bagetta V, Calabresi P, Picconi B. 2012. Functional interactions within striatal microcircuit in animal models of Huntington’s disease. Neuroscience. 211:165–184.
21. A receptor alterations in the human basal ganglia in Huntington’s disease. Neuroscience. 97:505–519.
22. Go BS, Ahn SM, Shim I, Choe ES. 2010. Activation of c-Jun N-terminal kinase is required for the regulation of endoplasmic reticulum stress response in the rat dorsal striatum following repeated cocaine administration. Neuropharmacology. 59:100–106.
23. Gomez JL, Bonaventura J, Lesniak W, Mathews WB, Sysa-Shah P, Rodriguez LA, Ellis RJ, Richie CT, Harvey BK, Dannals RF, et al. 2017. Chemogenetics revealed: DREADD occupancy and activation via converted clozapine. Science. 357:503–507.
24. Gu X, Li C, Wei W, Lo V, Gong S, Li SH, Iwasato T, Itohara S, Li XJ, Mody I, et al. 2005. Pathological cell-cell interactions elicited by a neuropathogenic form of mutant Huntingtin contribute to cortical pathogenesis in HD mice. Neuron. 46:433–444.
25. Han I, You Y, Kordower JH, Brady ST, Morfini GA. 2010. Differential vulnerability of neurons in Huntington’s disease: the role of cell type-specific features. J Neurochem. 113:1073–1091.
26. 1 receptor modulation of hippocampal LTD. Cell. 148:1039–1050.
27. Hedreen JC, Folstein SE. 1995. Early loss of neostriatal striosome neurons in Huntington’s disease. J Neuropath Exp Neur. 54: 105–120.
28. Horne EA, Coy J, Swinney K, Fung S, Cherry AE, Marrs WR, Naydenov AV, Lin YH, Sun X, Keene CD, et al. 2013. Downregulation of cannabinoid receptor 1 from neuropep-tide Y interneurons in the basal ganglia of patients with Huntington’s disease and mouse models. Eur J Neurosci. 37: 429–440.
29. Jansen AH, van Hal M, Op den Kelder IC, Meier RT, de Ruiter AA, Schut MH, Smith DL, Grit C, Brouwer N, Kamphuis W, et al. 2017. Frequency of nuclear mutant huntingtin inclusion formation in neurons and glia is cell-type-specific. Glia. 65:50–61.
30. Jayanthi S, McCoy MT, Ladenheim B, Cadet JL. 2002. Methamphetamine causes coordinate regulation of Src, Cas, Crk, and the Jun N-terminal kinase-Jun pathway. Mol Pharmacol. 61:1124–1131.
31. Jiang R, Diaz-Castro B, Looger LL, Khakh BS. 2016. Dysfunctional calcium and glutamate signaling in striatal astrocytes from Huntington’s disease model mice. J Neurosci. 36:3453–3470.
32. Katona I, Freund TF. 2008. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat Med. 14: 923–930.
33. Kreitzer AC. 2009. Physiology and pharmacology of striatal neurons. Annu Rev Neurosci. 32:127–147.
34. Kreitzer AC, Malenka RC. 2007. Endocannabinoid-mediated rescue of striatal LTD and motor deficits in Parkinson’s disease models. Nature. 445:643–647.
35. Kress GJ, Yamawaki N, Wokosin DL, Wickersham IR, Shepherd GM, Surmeier DJ. 2013. Convergent cortical innervation of striatal projection neurons. Nat Neurosci. 16:665–667.
36. Lee HM, Giguere PM, Roth BL. 2014. DREADDs: novel tools for drug discovery and development. Drug Discov Today. 19: 469–473.
37. Lei W, Jiao Y, Del Mar N, Reiner A. 2004. Evidence for differential cortical input to direct pathway versus indirect pathway striatal projection neurons in rats. J Neurosci. 24:8289–8299.
38. Martin R, Durroux T, Ciruela F, Torres M, Pin JP, Sanchez-Prieto J. 2010. The metabotropic glutamate receptor mGlu7 activates phospholipase C, translocates munc-13-1 protein, and potentiates glutamate release at cerebrocortical nerve terminals. J Biol Chem. 285:17907–17917.
39. Mathur BN, Lovinger DM. 2012. Endocannabinoid-dopamine interactions in striatal synaptic plasticity. Front Pharmacol. 3:66.
40. Maynard CJ, Bottcher C, Ortega Z, Smith R, Florea BI, Diaz-Hernandez M, Brundin P, Overkleeft HS, Li JY, Lucas JJ, et al. 2009. Accumulation of ubiquitin conjugates in a polyglutamine disease model occurs without global ubiquitin/proteasome system impairment. Proc Natl Acad Sci USA. 106:13986–13991.
41. 1) in Huntington’s disease transgenic mice. Eur J Biochem. 271:4909–4920.
42. McLaughlin BA, Nelson D, Erecinska M, Chesselet MF. 1998. Toxicity of dopamine to striatal neurons in vitro and potenti-ation of cell death by a mitochondrial inhibitor. J Neurochem. 70:2406–2415.
43. Meunier C, Merienne N, Jolle C, Deglon N, Pellerin L. 2016. Astrocytes are key but indirect contributors to the development of the symptomatology and pathophysiology of Huntington’s disease. Glia. 64:1841–1856.
44. 1 receptor knockout mice. Neurobiol Dis. 42:524–529.
45. Milnerwood AJ, Gladding CM, Pouladi MA, Kaufman AM, Hines RM, Boyd JD, Ko RW, Vasuta OC, Graham RK, Hayden MR, et al. 2009. Early increase in extrasynaptic NMDA receptor signaling and expression contributes to phenotype onset in Huntington’s disease mice. Neuron. 65:178–190.
46. Mitchell IJ, Griffiths MR. 2003. The differential susceptibility of specific neuronal populations: insights from Huntington’s disease. IUBMB Life. 55:293–298.
47. Monory K, Massa F, Egertova M, Eder M, Blaudzun H, Westenbroek R, Kelsch W, Jacob W, Marsch R, Ekker M, et al. 2006. The endocannabinoid system controls key epilepto-genic circuits in the hippocampus. Neuron. 51:455–466.
48. Murphy-Royal C, Dupuis J, Groc L, Oliet SH. 2017. Astroglial glutamate transporters in the brain: Regulating neurotransmitter homeostasis and synaptic transmission. J Neurosci Res. 95:2140–2151.
49. Navarrete M, Araque A. 2010. Endocannabinoids potentiate synaptic transmission through stimulation of astrocytes. Neuron. 68:113–126.
50. 1 receptors on medium spiny neurons prevents loss of excitatory striatal synapses but not motor impairment in HD mice. Neurobiol Dis. 71:140–150.
51. Okamoto SI, Pouladi MA, Talantova M, Yao D, Xia P, Ehrnhoefer DE, Zaidi R, Clemente A, Kaul M, Graham RK, et al. 2009. Balance between synaptic versus extrasynaptic NMDA receptor activity influences inclusions and neurotoxicity of mutant huntingtin. Nat Med. 15:1407–1413.
52. Paoletti P, Vila I, Rife M, Lizcano JM, Alberch J, Gines S. 2008. Dopaminergic and glutamatergic signaling crosstalk in Huntington’s disease neurodegeneration: the role of p25/ cyclin-dependent kinase 5. J Neurosci. 28:10090–10101.
53. Raymond LA, Andre VM, Cepeda C, Gladding CM, Milnerwood AJ, Levine MS. 2011. Pathophysiology of Huntington’s disease: time-dependent alterations in synaptic and receptor function. Neuroscience. 198:252–273.
54. Reiner A, Hart NM, Lei W, Deng Y. 2010. Corticostriatal projection neurons - dichotomous types and dichotomous functions. Front Neuroanat. 4:142.
55. Rikani AA, Choudhry Z, Choudhry AM, Rizvi N, Ikram H, Mobassarah NJ, Tulli S. 2014. The mechanism of degeneration of striatal neuronal subtypes in Huntington disease. Ann Neurosci. 21:112–114.
56. Rodriguez-Navarro JA, Gonzalo-Gobernado R, Herranz AS, Gonzlez-Vigueras JM, Solis JM. 2009. High potassium induces tau-rine release by osmosensitive and osmoresistant mechanisms in the rat hippocampus in vivo. J Neurosci Res. 87:208–217.
57. Ross CA, Aylward EH, Wild EJ, Langbehn DR, Long JD, Warner JH, Scahill RI, Leavitt BR, Stout JC, Paulsen JS, et al. 2014. Huntington disease: natural history, biomarkers and prospects for therapeutics. Nat Rev Neurol. 10:204–216.
58. Sepers MD, Raymond LA. 2014. Mechanisms of synaptic dysfunction and excitotoxicity in Huntington’s disease. Drug Discov Today. 19:990–996.
59. Silberberg G, Bolam JP. 2015. Local and afferent synaptic pathways in the striatal microcircuitry. Curr Opin Neurobiol. 33: 182–187.
60. Stella N. 2010. Cannabinoid and cannabinoid-like receptors in microglia, astrocytes, and astrocytomas. Glia. 58:1017–1030.
61. Suarez LM, Solis O, Carames JM, Taravini IR, Solis JM, Murer MG, Moratalla R. 2014. L-DOPA treatment selectively restores spine density in dopamine receptor D2-expressing projection neurons in dyskinetic mice. Biol Psychiatry. 75: 711–722.
62. Tang TS, Chen X, Liu J, Bezprozvanny I. 2007. Dopaminergic signaling and striatal neurodegeneration in Huntington’s disease. J Neurosci. 27:7899–7910.
63. Thu DC, Oorschot DE, Tippett LJ, Nana AL, Hogg VM, Synek BJ, Luthi-Carter R, Waldvogel HJ, Faull RL. 2010. Cell loss in the motor and cingulate cortex correlates with symptomatology in Huntington’s disease. Brain. 133:1094–1110.
64. Tong X, Ao Y, Faas GC, Nwaobi SE, Xu J, Haustein MD, Anderson MA, Mody I, Olsen ML, Sofroniew MV, et al. 2014. Astrocyte Kir4.1 ion channel deficits contribute to neuronal dysfunction in Huntington’s disease model mice. Nat Neurosci. 17:694–703.
65. Uchigashima M, Narushima M, Fukaya M, Katona I, Kano M, Watanabe M. 2007. Subcellular arrangement of molecules for 2-arachidonoyl-glycerol-mediated retrograde signaling and its physiological contribution to synaptic modulation in the striatum. J Neurosci. 27:3663–3676.
66. Unschuld PG, Joel SE, Liu X, Shanahan M, Margolis RL, Biglan KM, Bassett SS, Schretlen DJ, Redgrave GW, van Zijl PC, et al. 2012. Impaired cortico-striatal functional connectivity in prodromal Huntington’s Disease. Neurosci Lett. 514:204–209.
67. Walker FO. 2007. Huntington’s disease. Lancet. 369:218–228.
68. Wall NR, De La Parra M, Callaway EM, Kreitzer AC. 2013. Differential innervation of direct- and indirect-pathway striatal projection neurons. Neuron. 79:347–360.
69. Wang N, Gray M, Lu XH, Cantle JP, Holley SM, Greiner E, Gu X, Shirasaki D, Cepeda C, Li Y, et al. 2014. Neuronal targets for reducing mutant huntingtin expression to ameliorate disease in a mouse model of Huntington’s disease. Nat Med. 20:536–541.
70. Wang Z, Kai L, Day M, Ronesi J, Yin HH, Ding J, Tkatch T, Lovinger DM, Surmeier DJ. 2006. Dopaminergic control of corticostriatal long-term synaptic depression in medium spiny neurons is mediated by cholinergic interneurons. Neuron. 50:443–452.
71. Wu YW, Kim JI, Tawfik VL, Lalchandani RR, Scherrer G, Ding JB. 2015. Input- and cell-type-specific endocannabinoid-dependent LTD in the striatum. Cell Rep. 10:75–87.
72. Zeron MM, Hansson O, Chen N, Wellington CL, Leavitt BR, Brundin P, Hayden MR, Raymond LA. 2002. Increased sensitivity to N-methyl-D-aspartate receptor-mediated excitotoxicity in a mouse model of Huntington’s disease. Neuron. 33:849–860.